Publications: Dr Mark-Alexander Schwarzbich

Back to Search

Kriegsmann K, Rieger M, Schwarzbich M-A, Sitter S, Kriegsmann M, Bruckner T, Hensel M, Ho AD et al.(2018). Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol vol. 101, (1) 12-20.

10.1111/ejh.13064

Schwarzbich M-A, Witzens-Harig M(2017). Cellular Immunotherapy in B-Cell Malignancy. Oncol Res Treat vol. 40, (11) 674-681.

10.1159/000481946

Lisenko K, Cremer M, Schwarzbich M-A, Kriegsmann M, Ho AD, Wuchter P, Witzens-Harig M (2017). Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with DLBCL. ONCOLOGY RESEARCH AND TREATMENT. vol. 40, 157-157.

Cremer M, Schwarzbich M-A, Schöning T, Lisenko K, Ho AD, Witzens-Harig M(2017). In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study. Ann Hematol vol. 96, (9) 1573-1575.

10.1007/s00277-017-3044-4

Lehners N, Krämer I, Schwarzbich M-A, Ho AD, Witzens-Harig M(2016). Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk Lymphoma vol. 57, (11) 2619-2625.

10.3109/10428194.2016.1157869

Lisenko K, Cremer M, Schwarzbich M-A, Kriegsmann M, Ho AD, Wuchter P, Witzens-Harig M (2016). Efficient stem cell collection after modified cisplatin-based mobilization chemotherapy in patients with DLBCL. ONCOLOGY RESEARCH AND TREATMENT. vol. 39, 157-157.

Schwarzbich MA, Schöning T, Cremer M, Lisenko K, Ho AD, Witzens-Harig M(2016). Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment. Leukemia and Lymphoma vol. 57, (7) 1723-1726.

10.3109/10428194.2015.1113274

Schwarzbich MA, McClanahan F, DSc JGR(2016). Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies. Oncology (Williston Park, N.Y.) vol. 30, (6)

Schwarzbich M-A, McClanahan F, Gribben J(2016). Allogeneic Transplantation for Chronic Lymphocytic Leukemia in the Age of Novel Treatment Strategies. Oncology (Williston Park) vol. 30, (6) 526-540.

Lisenko K, McClanahan F, Schöning T, Schwarzbich MA, Cremer M, Dittrich T, Ho AD, Witzens-Harig M(2016). Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma. BMC Cancer vol. 16, (1)

10.1186/s12885-016-2289-y

Lisenko K, Cremer M, Schwarzbich M-A, Kriegsmann M, Ho AD, Witzens-Harig M, Wuchter P(2016). Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation

10.1016/j.bbmt.2016.03.030

Schmidt K, Kellner K-H, Radujkovic A, Lehners N, Schwarzbich M-A, Hegenbart U, Ho A, Dreger P et al. (2016). ATG and statins reduce incidence of severe chronic GVHD by distinct mechanisms - influence of Vitamin B6. BONE MARROW TRANSPLANTATION. vol. 51, S386-S387.

Madle M, Krämer I, Lehners N, Schwarzbich M, Wuchter P, Herfarth K, Egerer G, Ho AD et al.(2015). The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma. Ann Hematol vol. 94, (11) 1853-1857.

10.1007/s00277-015-2470-4

Cremer M, Schwarzbich M-A, Schoening T, Lisenko K, Ho AD, Witzens-Harig M (2015). Burkitt lymphoma treated with a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002): A single-center retrospective analysis of efficacy, toxicity and experience with relapsed/refractory disease. Oncology Research and Treatment. vol. 38, 67-67.

Lisenko K, McClanahan F, Schoening T, Schwarzbich M-A, Cremer M, Dittrich T, Ho AD, Witzens-Harig M(2015). Minimal renal toxicity after Rituximab-DHAP with a modified cisplatin application scheme in patients with relapsed and refractory diffuse large B-cell lymphoma. Oncology Research and Treatment vol. 38, 199-199.

Schwarzbich M-A, Schmidt K, Lehners N, Falk C, Ho A, Dreger P, Luft T (2015). High VEGF serum levels on days+50 and+100 after allogeneic stem cell transplantation predict severe chronic GvHD. BONE MARROW TRANSPLANTATION. vol. 50, S379-S380.

Schmidt K, Schwarzbich M-A, Lehners N, Dreger P, Luft T (2015). Incidence of severe chronic GVHD is reduced either by ATG or by statins. BONE MARROW TRANSPLANTATION. vol. 50, S181-S182.

Madle M, Kraemer I, Lehners N, Schwarzbich M-A, Wuchter P, Egerer G, Ho AD, Witzens-Harig M (2015). The influence of rituximab, high dose therapy followed by autologous stem cell transplantation and age in patients with primary CNS-lymphoma. BONE MARROW TRANSPLANTATION. vol. 50, S284-S284.

Schwarzbich M-A, Schoening T, Maximillian M, Ho AD, Witzens-Harig M (2014). Efficacy of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients. ONCOLOGY RESEARCH AND TREATMENT. vol. 37, 142-142.

Madle M, Herth I, Lehners N, Schwarzbich M, Wuchter P, Egerer G, Ho AD, Witzens-Harig M (2014). Rituximab, age and high dose therapy followed by autologus stem cell transplantation are independent prognostic factors for survival in the first line treatment of primary CNS-lymphoma. ONCOLOGY RESEARCH AND TREATMENT. vol. 37, 10-10.

Schwarzbich M-A, Witzens-Harig M(2014). Ibrutinib. Recent Results Cancer Res vol. 201, 259-267.

10.1007/978-3-642-54490-3_17

Braun S, Gutknecht M, Kanz L, Salih HR, Gruenebach F, Rittig SM, Schwarzbich MA (2012). Upregulation of immunoinhibitory receptor Osteoactivin on human monocyte-derived dendritic cells by immunosuppressive drugs. ONKOLOGIE. vol. 35, 60-60.

Schwarzbich M-A, Gutknecht M, Salih J, Salih HR, Brossart P, Rittig SM, Grünebach F(2012). The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother vol. 61, (2) 193-202.

10.1007/s00262-011-1096-1

Gutknecht M, Schwarzbich M-A, Kanz L, Salih HR, Gruenebach F, Rittig SM (2011). Immunosuppressive drugs upregulate the immune inhibitory receptor osteoactivin in monocyte-derived dendritic cells. ONKOLOGIE. vol. 34, 169-169.

Schwarzbich M-A, Schmidt SM, Gutknecht M, Salih J, Kanz L, Salih HR, Gruenebach F (2010). The immune inhibitory receptor osteoactivin is up-regulated in monocyte-derived dendritic cells by tyrosine kinase inhibitors. ONKOLOGIE. vol. 33, 275-275.

Back to Search